Dr James Foran speaks to ecancer at the ASH 2019 meeting in Orlando about the ECOG-ACRIN (E-A) E2906 randomised study evaluating maintenance decitabine after intensive therapy for AML in older patients who are particularly FLT3-ITD-negative.
He explains that patients who were in complete remission were randomised 1:1 onto a maintenance treatment for a year vs observation.
Dr Foran reports that the maintenance decitabine was well tolerated and improves disease-free and overall survival.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.